(Q36613420)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

title

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

0 references

1 reference

ChEBI release 2020-05-28

Christian Confavreux

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

David K Li

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Mark S Freedman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Philippe Truffinet

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Hadj Benzerdjeb

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Dazhe Wang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Lucy E Reiman

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Paul W O'Connor

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Teriflunomide Multiple Sclerosis Trial Group

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

3 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

22 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

page(s)

1278-1289

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

Pathophysiology of multiple sclerosis and the place of teriflunomide

22 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573681

A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573681

Mechanism of action for leflunomide in rheumatoid arthritis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573681

Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573681

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573681

Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573681

A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3573681

20 September 2018

Identifiers

DOI

10.1177/1352458512436594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

PubMed publication ID

22307384

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22307384%20AND%20SRC:MED&resulttype=core&format=json